pentobarbital will reduce the level or influence of theophylline by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.

Monitor Closely (1)pentobarbital will reduce the extent or influence of benzhydrocodone/acetaminophen by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Intently. Warning when discontinuing CYP3A4 inducers which might be coadministered with benzhydrocodone (prodrug of hydrocodone); plasma concentrations of hydrocodone could improve and can result in likely lethal respiratory melancholy.

pentobarbital will reduce the level or result of pimavanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check. Stay clear of coadministration if at all possible. Monitor for lessened pimavanserin efficacy. An increase in pimavanserin dosage may be wanted.

pentobarbital will minimize the level or influence of ixabepilone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.

pentobarbital will decrease the level or impact of repaglinide by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.

pentobarbital will lower the extent or impact of ziprasidone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unfamiliar.

pentobarbital will lessen the extent or effect of eplerenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Not known.

pentobarbital increases outcomes of ifosfamide by affecting hepatic enzyme CYP2B6 metabolism. Use Warning/Keep track of. Coadministration of ifosfamide with CYP2B6 inducers might boost metabolism of ifosfamide to its metabolite. Monitor for enhanced consequences/toxicities if combined with CYP2B6 inducers.

Breastfeeding things to consider: read more In breastfeeding concerns, it should be pointed out that barbiturates are present in breast milk.

pentobarbital decreases levels of vandetanib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Keep away from coadministration with strong CYP3A4 inducers; these prescription drugs lessen exposure to vandetanib by up to forty%.

pentobarbital will lessen the level or outcome of parecoxib by impacting hepatic enzyme CYP2C9/ten metabolism. Use Warning/Monitor.

pentobarbital will lessen the extent or outcome of venetoclax by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

pentobarbital will lessen the extent or impact of clarithromycin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Unfamiliar.

pentobarbital will decrease the level or effect of apremilast by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with strong CYP inducers brings about an important minimize of systemic publicity of apremilast, which can end in lack of efficacy